KHRN.V - Khiron Life Sciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
2.4700
-0.1600 (-6.08%)
At close: 4:15PM EDT
Stock chart is not supported by your current browser
Previous Close2.6300
Open2.6300
Bid2.4500 x 0
Ask2.4700 x 0
Day's Range2.4600 - 2.6300
52 Week Range0.8700 - 4.3500
Volume387,992
Avg. Volume951,193
Market Cap254.442M
Beta (3Y Monthly)3.98
PE Ratio (TTM)N/A
EPS (TTM)-0.4360
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • PR Newswire2 days ago

    Khiron Announces Changes to Leadership Team with Appointment of Wendy Kaufman as CFO

    TORONTO, June 14, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), a cannabis company with core operations in Latin America, today announced the appointment of Wendy Kaufman as CFO, effective July 2, 2019. Ms. Kaufman, a Chartered Professional Accountant, brings over 20 years of international financial experience, having served most recently as CFO at Pasinex Resources Limited.  Ms. Kaufman has significant experience with Latin American operations, gained during her tenure as CFO at Primero Mining Corporation, and previously in her role as Vice President, Finance and Treasury at Inmet Mining Corporation, among other executive management positions.

  • CNW Group9 days ago

    Khiron Receives Regulatory Approval for Uruguay Acquisition

    TORONTO , June 7, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America reports that the Company's previously announced agreement for the acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"), is progressing as planned. On June 5, 2019 , the Company secured local regulatory approvals in Uruguay for the completion of the Acquisition.

  • Cronos Stock Is Lagging Other Marijuana Names
    InvestorPlace10 days ago

    Cronos Stock Is Lagging Other Marijuana Names

    After receiving the backing of Altria Group Inc (NYSE:MO), Canada-based cannabis producer Cronos Group (NASDAQ:CRON) looked like it was headed for significant growth, but it has not delivered. As a result, the performance of CRON stock has been disappointingSince the deal, CRON has not made meaningful strides in production, which is the name of the game in cannabis, nor has the company expanded notably overseas. Without even factoring in the valuation of CRON stock, I have serious concerns about the company.CRON just does not have strong enough fundamentals to propel Cronos stock meaningfully higher. The company continues to lag its competitors in production, R&D, and new markets.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Could Be Takeover Targets Capacity WoesCronos' production capacity is comparable to the likes of Organigram and CannTrust Holdings (NYSE:CTST), but the market gives CRON stock a substantially larger valuation.However, it is not clear why that gap is justified, since CRON is a less efficient grower and seller than its two competitors.Cronos, Organigram, and CannTrust Holdings all have similar capacity now and similar estimated capacity next year. Looking at recent results, though, Cronos clearly grows cannabis less efficiently and sells it less effectively. Cronos sold just 1,111 kg of cannabis last year, while Organigram sold 4,248 kg and CannTrust sold over 3,000 kg.Cronos is falling behind tremendously. CRON Doesn't Have an Edge OverseasCRON's international push does not seem to be materially different or more successful than that of its peers. Most of its overseas partnerships are in very competitive areas. Other players have been expanding much more aggressively, and CRON has less ground cultivated overseas than the competition, which will be a hindrance to its growth and to CRON stock.In Australia, for example, Cronos is aiming for annual production capacity of 2,000 kg. But that is peanuts compared to what Solaris Nutraceuticals Pty Ltd is doing. Its greenhouse will produce around 100,000 kg per year of medical cannabis.In Latin America, CRON has a 50/50 joint venture with AGI, Colombia's leading agricultural services provider. However, there has been a big increase in the number of cultivators in the region. Again, just as an example. AGI's 207 acres of available land pales in comparison to competitors like Colombia's Pharmacielo, which has over 15 million square feet of land. That translates roughly to production capacity of over 5,000 kilograms.There's also Khiron, a Colombian grower that has been expanding its own cultivation area. Its total area is estimated to be capable of producing 100,000 kilograms of dry flower for extraction and processing into medical cannabis.You get the idea.Europe is even more crowded. Germany and Poland, where many American-listed Canadian companies have been active in M&A and expanding their footprints, are particularly competitive. The Bottom Line on CRON StockThe cannabis industry is a very attractive space to be in, but there are bound to be some duds. At the moment, Cronos Group stock is shaping up to be a good name to short. One caveat is that Cronos does has a decent cash balance.Overall, investors can always generate profits by reducing exposure to the laggards and doubling down on the leaders. Investors should be reducing their exposure to CRON stock.As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 4 FANG Stocks Won't Be Bitten By Regulation Threats * 10 Stocks to Buy That Could Be Takeover Targets * 4 Big Bank Stocks Rebounding Compare Brokers The post Cronos Stock Is Lagging Other Marijuana Names appeared first on InvestorPlace.

  • PR Newswire10 days ago

    Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations NEW YORK , June 6, 2019 /PRNewswire/ -- Virtual Investor Conferences ...

  • Market Exclusive11 days ago

    Cannabis Stock News Daily Roundup June 5

    High Tide (CSE: HITI) (OTCQB: HITIF) (FRA: 2LY) has opened a new Smoker's Corner retail store in the Royal Chapelle Area of Edmonton in Edmonton, Alberta. The Royal Chapelle Store will be supplied from the company's vast catalog of more than 4,300 SKUs of smoking accessories and cannabis lifestyle products, including the full range of proprietary […]The post Cannabis Stock News Daily Roundup June 5 appeared first on Market Exclusive.

  • Market Exclusive12 days ago

    Khiron Announces Completion Of Ibague Colombia Facility

    Khiron Life Sciences Corp (OTCMKTS:KHRNF) has announced the completion of construction and the start of operations for growing, extraction and processing in the Ibague Colombia facility. Progress has been made regarding commercial registration as well as the production of medical cannabis products that target over 6 million patients in Latin America . Milestones and progress […]The post Khiron Announces Completion Of Ibague Colombia Facility appeared first on Market Exclusive.

  • /R E P E A T -- Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year/
    PR Newswire13 days ago

    /R E P E A T -- Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year/

    TORONTO, June 2, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce the completion of construction and the initiation of operations in its cultivation, extraction, and analysis facilities in Ibague, Colombia, where significant progress has been made towards the commercial registration and production of medical cannabis products targeting 6 million potential patients across the country. Khiron currently owns and operates one of the most sophisticated medical cannabis cultivation and processing facilities in Latin America.

  • Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year
    PR Newswire14 days ago

    Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year

    TORONTO, June 2, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce the completion of construction and the initiation of operations in its cultivation, extraction, and analysis facilities in Ibague, Colombia, where significant progress has been made towards the commercial registration and production of medical cannabis products targeting 6 million potential patients across the country. Khiron currently owns and operates one of the most sophisticated medical cannabis cultivation and processing facilities in Latin America.

  • Market Exclusive16 days ago

    Khiron Life Sciences Added to ETFMG Alternative Harvest ETF

    Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF), a cannabis company with core operations in Latin America, said that it has been added the MJ ETFMG Alternative Harvest ETF (NYSE: MJ), a fund with approximately US$1.22 billion in assets currently under management. The company calls it an important development as it advances its strategy as a […]The post Khiron Life Sciences Added to ETFMG Alternative Harvest ETF appeared first on Market Exclusive.

  • PR Newswire16 days ago

    Live Investor Conference & Webinar: Cannabis Industry Companies Present June 4th

    Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , May 31, 2019 /PRNewswire/ -- Virtual Investor Conferences and KCSA Strategic Communications ...

  • CNW Group16 days ago

    Khiron Life Sciences Reports First Quarter Fiscal 2019 Financial Results

    Khiron Life Sciences Reports First Quarter Fiscal 2019 Financial Results

  • PR Newswire17 days ago

    Khiron Life Sciences to Webcast Live on June 4th at VirtualInvestorConferences.com

    Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com TORONTO , May 30, 2019 /PRNewswire/ ...

  • CNW Group18 days ago

    Khiron Announces Addition to $1.2B MJ ETFMG Alternative Harvest ETF

    TORONTO , May 29, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America is pleased to announce today its addition to the MJ ETFMG Alternative Harvest ETF (MJ) (the "Fund"), a fund with approximately US$1.22 billion in assets currently under management. This represents an important development for the Company as it advances its strategy as a Latin American cannabis company with global growth. The Fund tracks the Prime Alternative Harvest Index, designed to measure the performance of companies within the cannabis ecosystem benefiting from global medicinal and recreational cannabis legalization.

  • CNW Group19 days ago

    Khiron Announces Closing of $28.75 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option

    TORONTO , May 28, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America is pleased to announce that it has closed today its previously announced "bought deal" short form prospectus offering of common shares ("Common Shares"), including the exercise in full of the over-allotment option (the "Offering"). A total of 9,914,150 Common Shares were sold at a price of $2.90 per Common Share (the "Issue Price") for aggregate gross proceeds of $28,751,035 (including the exercise in full of the over-allotment option).

  • Are Insiders Buying Khiron Life Sciences Corp. (CVE:KHRN) Stock?
    Simply Wall St.22 days ago

    Are Insiders Buying Khiron Life Sciences Corp. (CVE:KHRN) Stock?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • CNW Grouplast month

    Khiron Provides Update on Transaction to Acquire NettaGrowth

    TORONTO , May 13, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America, reports that the Company's previously announced agreement for the acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"), is progressing as planned and the Company is in the latter stages of securing local regulatory approvals in Uruguay for the completion of the Acquisition.

  • CNW Grouplast month

    Khiron Mails and Files Circular Relating to its Annual General and Special Meeting of Shareholders

    Proxy voting deadline is May 29, 2019 at 11 a.m. ( Toronto time). Board of Directors recommends that Shareholders vote FOR all resolutions. TORONTO , May 10, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America, today announced it has commenced the mailing of the management information circular and other related materials (collectively, the "Meeting Materials") to Khiron's shareholders ("Shareholders") in connection with the annual general and special meeting of Shareholders (the "Meeting").

  • CNW Grouplast month

    /C O R R E C T I O N from Source -- Khiron Life Sciences Corp./

    In the news release, Khiron Life Sciences Enters into $25 Million Bought Deal Equity Financing, issued 06-May-2019 by Khiron Life Sciences Corp. over CNW, we are advised by the company that the first paragraph, last sentence, should read "Common Share of $2.90 " rather than "Common Share of $3.00 " as originally issued inadvertently. TORONTO , May 6, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America , announced today that it has entered into an agreement with Canaccord Genuity Corp. and BMO Capital Markets as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters (together, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, 8,621,000 common shares of the Company ("Common Shares"), on a "bought deal" basis pursuant to a short form prospectus offering, subject to all required regulatory approvals, at a price per Common Share of $2.90 (the "Issue Price") for gross proceeds of $25,000,900 (the "Offering").